Perioperative systemic treatments in renal cell carcinoma

Rohit Goswamy; Ecem Kalemoglu; Viraj Master; Mehmet Asim Bilen

doi:10.3389/fonc.2024.1362172

Perioperative systemic treatments in renal cell carcinoma

Front Oncol. 2024 May 21:14:1362172. doi: 10.3389/fonc.2024.1362172. eCollection 2024.

Authors

Rohit Goswamy^{1

2}, Ecem Kalemoglu³, Viraj Master^{2

4}, Mehmet Asim Bilen^{1

2}

Affiliations

¹ Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States.
² Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States.
³ Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, United States.
⁴ Department of Urology, Emory University School of Medicine, Atlanta, GA, United States.

Abstract

In this review, we aim to provide a comprehensive assessment of the evolving landscape of the perioperative management in renal cell carcinoma (RCC), emphasizing its dynamic and intricate nature. We explore academic and clinical insights into the perioperative treatment paradigm of RCC. Up-to-date treatment options are discussed and the evolving role of neoadjuvant and adjuvant therapy in RCC is highlighted.

Keywords: RCC (Renal Cell Carcinoma); adjuvant; cancer; kidney cancer; neoadjuvant; outcomes; renal cell carcinoma; review.

Publication types

Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.